Mirum Pharmaceuticals, Inc. MIRM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -139.8%-120pp | -4.2%+21.8pp | -8.9%+22.4pp | -13.3%+27.7pp | -20.1%+28.3pp | |
| Net margin | -140.2%-120pp | -4.5%+21.6pp | -8.8%+23.7pp | -13.6%+27.6pp | -20.4%+50.4pp | |
| EBITDA margin | -135.4%-122pp | 0.4%+19.4pp | -3.7%+20.0pp | -7.7%+25.9pp | -13.8%+27.9pp | |
| Free cash flow margin | -30.3%— | 10.5%— | —— | —— | —— | |
| Returns | ||||||
| Return on equity | -335.8%-303pp | -8.6%+28.4pp | -15.8%+24.0pp | -24.2%+46.8pp | -33.1%+51.3pp | |
| Return on assets | -101%-89.5pp | -3.1%+10.3pp | -5.7%+9.4pp | -8.4%+11.3pp | -11.5%+20.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.2× | 0.7×+0.2× | 0.6×+0.2× | 0.6×+0.1× | 0.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.1×-1.1× | 2.7×-0.4× | 3.3×0.0× | 3.1×-0.1× | 3.2×-0.5× | |
| Quick ratio | 2×-1.1× | 2.6×-0.4× | 3.2×0.0× | 3×-0.1× | 3×-0.4× | |
| Cash ratio | 1×-0.5× | 1.2×-0.4× | 1.4×-0.3× | 1.3×-0.6× | 1.4×-1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -55.3×-49.9× | -1.5×+4.6× | -2.9×+3.8× | -4×+3.6× | -5.3×+2.2× | |
| Per Share | ||||||
| Book value per share | $4.12-13.6% | $6.27+32.0% | $5.12+5.5% | $5.13+5.8% | $4.77-4.6% | |
| Valuation | ||||||
| Market capitalization | $5.57B+152% | $4.08B+106% | $3.68B+99.9% | $2.53B+57.8% | $2.21B+88.1% | |
| Enterprise value | $5.33B+162% | $3.84B+114% | $3.46B+109% | $2.35B+67.5% | $2.03B+128% | |
| Price / sales | 9.8×+4.0× | 7.8×+1.9× | 7.8×+1.8× | 5.9×-0.2× | 5.8×+0.6× | |
| Price / book | 23×+13.5× | 13×+4.2× | 12.6×+4.7× | 9.9×+2.9× | 9.5×+4.5× | |
| EV / sales | 9.4×+4.0× | 7.4×+2.0× | 7.3×+1.9× | 5.5×+0.2× | 5.4×+1.4× | |
| Free cash flow yield | -3.1%— | 1.3%— | —— | —— | —— | |
| Earnings yield | -14.3%-10.8pp | -0.6%+3.9pp | -1.1%+4.3pp | -2.3%+4.5pp | -3.5%+10.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mirum Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Mirum Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
